Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study

World Journal of Biological Psychiatry

Volumn 15, Issue 1, 2014, Pages 26-35

  Apostolopoulou, Konstantina ^a   Künzel, Heike E ^a   Gerum, Sabine ^b   Merkle, Katrin ^a   Schulz, Sebastian ^a   Fischer, Evelyn ^a   Pallauf, Anna ^a   Brand, Volker ^a   Bidlingmaier, Martin ^a   Endres, Stephan ^a   Beuschlein, Felix ^a   Reincke, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aldosterone; Anxiety; Arterial hypertension; Conn's syndrome; Depression; Renin

Indexed keywords

DOXAZOSIN; EPLERENONE; FUROSEMIDE; HORMONE; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE; VERAPAMIL;

ADRENALECTOMY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; GAD 7 SCALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; MIDDLE AGED; PHQD SCALE; PLASMA RENIN ACTIVITY; PREDICTIVE VALUE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SYMPTOM;

ADRENALECTOMY; ADULT; AGE FACTORS; AGED; ANXIETY; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PILOT PROJECTS; REGISTRIES; SEX FACTORS; TIME FACTORS;

EID: 84892428891     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2012.665480     Document Type: Article

References (69)

1. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 1997. ' Vascular depression ' hypothesis. Arch Gen Psychiatry 54:915-922.
2. Anstey KJ, Burns R, Butterworth P, Windsor TD, Christensen H, Sachdev, P. 2009. Cardiovascular risk factors and life events as antecedents of depressive symptoms in middle and early-old age: PATH Through Life Study. Psychosom Med 71: 937-943.
3. Avery TL. 1984. Primary hyperaldosteronism and depression. N Z Med J 97:537.
4. Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, et al. 2006. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 11:1003-1015. (Pubitemid 44631643)
5. Barden N, Reul JM, Holsboer F. 1995. Do antidepressants stabilize mood through actions on the hypothalamic-pituitaryadrenocortical system Trends Neurosci 18:6-11.
6. Binder EB, Kunzel HE, Nickel T, Kern N, Pfennig A, Majer M, et al. 2009. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 34: 99-109.
7. Bitran D, Shiekh M, Dowd JA, Dugan MM, Renda P. 1998. Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol Biochem Behav 60:879-887. (Pubitemid 28349949)
8. Blanchard-Fields F, Irion JC. 1988a. Coping strategies from the perspective of two developmental markers: age and social reasoning. J Genet Psychol 149:141-151.
9. Blanchard-Fields F, Irion JC. 1988b. The relation between locus of control and coping in two contexts: age as a moderator variable. Psychol Aging 3:197-203.
10. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. 2009. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94:1125-1130
11. Briones-Aranda A, Castillo-Salazar M, Picazo O. 2009. Adrenalectomy modifi es the hippocampal 5-HT(1A) receptors and the anxiolytic-like effect of 8-OH-DPAT in rats. Pharmacol Biochem Behav 92:182-189.
12. Brown AD, Barton DA, Lambert GW. 2009. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 23:583-602.
13. Carney RM, Freedland KE. 2009. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 166:410-417.
14. Chalmers DT, Kwak SP, Mansour A, Akil H, Watson SJ. 1993.Corticosteroids regulate brain hippocampal 5-HT1A receptor mRNA expression. J Neurosci 13:914-923. (Pubitemid 23067581)
15. Chen PS, McQuoid DR, Payne ME, Steffens DC. 2006. White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study. Int Psychogeriatr 18:445-456. (Pubitemid 44128318)
16. Dafer RM, Rao M, Shareef A, Sharma A. 2008. Poststroke depression. Top Stroke Rehabil 15:13-21. (Pubitemid 351160087)
17. Daig I, Herschbach P, Lehmann A, Knoll N, Decker O. 2009.Gender and age differences in domain-specifi c life satisfaction and the impact of depressive and anxiety symptoms: a general population survey from Germany. Qual Life Res 18:669-678.
18. de Kloet ER, Joels M, Holsboer F. 2005. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463-475. (Pubitemid 40769171)
19. de Kloet ER, Karst H, Joels M. 2008. Corticosteroid hormones in the central stress response: quick-and-slow. Front Neuroendocrinol 29:268-272.
20. Dobson KS. 1985. An analysis of anxiety and depression scales. J Pers Assess 49:522-527. (Pubitemid 16227553)
21. Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. 2005. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 36:544-548. (Pubitemid 41140063)
22. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. 2011.Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 12:43-48.
23. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. 2008. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-3281.
24. Gilbody S, Richards D, Brealey S, Hewitt C. 2007. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 22:1596-1602. (Pubitemid 47568684)
25. Golden SH, Lee HB, Schreiner PJ, Roux AD, Fitzpatrick AL, Szklo M, et al. 2007. Depression and type 2 diabetes mellitus: the multiethnic study of atherosclerosis. Psychosom Med 69:529-536. (Pubitemid 47205736)
26. Hamarat E, Thompson D, Aysan, F, Steele, D, Matheny, K, Simons, C. 2002. Age differences in coping resources and satisfaction with life among middle-aged, young-old, and oldestold adults. J Genet Psychol 163:360-367.
27. Hlavacova N, Jezova D. 2008. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 54:90-97.
28. Holmes MC, Yau JL, French KL, Seckl JR. 1995. The effect of adrenalectomy on 5-hydroxytryptamine and corticosteroid receptor subtype messenger RNA expression in rat hippocampus. Neuroscience 64:327-337.
29. Holsboer F. 1999. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33:181-214. (Pubitemid 29178663)
30. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
31. Holsboer F. 2001. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 62:77-91. (Pubitemid 32126613)
32. Joels M, Karst H, DeRijk R, de Kloet ER. 2008. The coming out of the brain mineralocorticoid receptor. Trends Neurosci 31:1-7.
33. Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. 2009.Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J Psychopharmacol 23:985-987.
34. Kellner M, Wiedemann K. 2008. Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. Eur J Pharmacol 583:372-378.
35. Khurshid KA, Weaver ME. 2005. Conn's syndrome presenting as depression. Am J Psychiatry 162:1226.
36. Komukai K, Mochizuki S, Yoshimura M. 2010. Gender and the renin-angiotensin-aldosterane system. Fundam Clin Pharmacol 24:687-98.
37. Korte SM, de Boer SF, de Kloet ER, Bohus B. 1995. Anxiolyticlike effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plusmaze. Psychoneuroendocrinology 20:385-394.
38. Kuroda Y, Watanabe Y, Albeck DS, Hastings NB, McEwen BS. 1994. Effects of adrenalectomy and type I or type II glucocorticoid receptor activation on 5-HT1A and 5-HT2 receptor binding and 5-HT transporter mRNA expression in rat brain. Brain Res 648:157-161. (Pubitemid 24171585)
39. Lippi G, Montagnana M, Favaloro EJ, Franchini M. 2009. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 35:325-336.
40. Lopez JF, Chalmers DT, Little KY, Watson SJ. 1998. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 43:547-573. (Pubitemid 28198224)
41. Lopez JF, Liberzon I, Vazquez DM, Young EA, Watson SJ. 1999. Serotonin 1A receptor messenger RNA regulation in the hippocampus after acute stress. Biol Psychiatry 45:934-937. (Pubitemid 29185487)
42. Malinow KC, Lion JR. 1979. Hyperaldosteronism (Conn's disease) presenting as depression. J Clin Psychiatry 40:358-359. (Pubitemid 9232899)
43. Meijer OC, de Kloet ER. 1994. Corticosterone suppresses the expression of 5-HT1A receptor mRNA in rat dentate gyrus. Eur J Pharmacol 266:255-261.
44. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. 2003. Primary aldosteronism and hypertensive disease. Hypertension 42:161-165. (Pubitemid 36944590)
45. Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A. 2003. The renin-angiotensin-aldosterone system in patients with depression compared to controls-a sleep endocrine study. BMC Psychiatry 3:15.
46. Murck H, Uhr M, Ziegenbein M, Kunzel H, Held K, Antonijevic IA, et al. 2006. Renin-angiotensin-aldosterone system, HPA-axis and sleep-EEG changes in unmedicated patients with depression after total sleep deprivation. Pharmacopsychiatry 39:23-29. (Pubitemid 43235447)
47. Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. 2010. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 44:339-346.
48. Panagiotakos DB, Kinlaw M, Papaerakleous N, Papoutsou S, Toutouzas P, Polychronopoulos E. 2008. Depressive symptomatology and the prevalence of cardiovascular risk factors among older men and women from Cyprus. the MEDIS (Mediterranean Islands Elderly) epidemiological study. J Clin Nurs 17:688-695.
49. Pariante CM, Miller AH. 2001. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49:391-404. (Pubitemid 32234301)
50. Parker G, Brotchie H. 2010. Gender differences in depression. Int Rev Psychiatry 22:429-436.
51. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al. 2009. Risk factors associated with a low glomerular fi ltration rate in primary aldosteronism. J Clin Endocrinol Metab 94:869-875.
52. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, et al. 2010. Is primary aldosteronism associated with diabetes mellitus Results of the German Conn's Registry. Horm Metab Res 42:435-439.
53. Reul JM, Stec I, Soder M, Holsboer F. 1993. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312-320. (Pubitemid 23206409)
54. Rief W, Nanke A, Klaiberg A, Braehler E. 2004. Base rates for panic and depression according to the Brief Patient Health Questionnaire: a population-based study. J Affect Disord 82:271-276. (Pubitemid 39370829)
55. Ruiz MA, Zamorano E, Garcia-Campayo J, Pardo A, Freire O, Rejas, J. 2010. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord.
56. Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, et al. 2009. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 106: 305-311.
57. Schussler P, Yassouridis A, Uhr M, Kluge M, Bleninger P, Holsboer F, et al. 2010. Sleep and active renin levels-interaction with age, gender, growth hormone and cortisol. Neuropsychobiology 61:113-121.
58. Seckl JR, Fink G. 1992. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55:621-626.
59. Smythe JW, Murphy D, Timothy C, Costall B. 1997. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacol Biochem Behav 56:507-513. (Pubitemid 27145833)
60. Sonino N, Fallo F, Fava GA. 2006. Psychological aspects of primary aldosteronism. Psychother Psychosom 75: 327-330. (Pubitemid 44200481)
61. Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. 2011. Psychological Assessment of Primary Aldosteronism: A Controlled Study. J Clin Endocrinol Metab. 96:383-6.
62. Vonend O, Quack I, Rump LC. 2010. [The role of aldosterone in hypertension]. Wien Klin Wochenschr 122:65-74.
63. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. 2008.Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 13:786-799, 741.
64. Watkins LL, Blumenthal JA, Davidson JR, Babyak MA, McCants CB Jr, Sketch M. H Jr. 2006. Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med 68:651-656. (Pubitemid 44454631)
65. Yau JL, Olsson T, Morris RG, Meaney MJ, Seckl JR. 1995. Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience 66:571-581.
66. Yau JL, Noble J, Hibberd C, Seckl JR. 2001. Short-term administration of fl uoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 306:161-164. (Pubitemid 32530824)
67. Yau JL, Hibberd C, Noble J, Seckl JR. 2002. The effect of chronic fl uoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res 106:117-123. (Pubitemid 35223284)
68. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. 2003. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60:24-28. (Pubitemid 36070861)
69. Zhong P, Ciaranello RD. 1995. Transcriptional regulation of hippocampal 5-HT1a receptors by corticosteroid hormones. Brain Res Mol Brain Res 29:23-34.